Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

In a real-world study involving patients with standard-risk, newly-diagnosed multiple ... death or progression were reported, with 10 occurring in the tandem ASCT group (50%) and 22 occurring in the ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The National Cancer Institute estimates that in the United States, slightly over 35,000 people will be diagnosed with multiple myeloma by the end of 2024. That rate has been fairly stable for the ...

Sharda Sinha, popularly known as 'Bihar Kokila' and known for her songs in Bhojpuri, Maithili, and Hindi languages, succumbed ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

It was once the standard of care for patients with relapsed or refractory multiple myeloma. Overall response rate (ORR): percentage of patients who have a partial response to treatment (tumor ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma ...